Lachman Consultant Services Inc. mishandled filing Pharmathen SA’s application to make a generic version of the blockbuster multiple sclerosis drug Tecfidera, according to a new lawsuit.
The suit, filed Nov. 21 in the U.S. District Court for the Southern District of New York, alleges the consulting firm negligently caused Pharmathen to lose out on first-to-file exclusivity rights on generic Tecfidera. The first generic applicant to challenge the patent on a drug is eligible for six months of market exclusivity on the generic (Pharmathen S.A. v. Lachman Consultant Services Inc., S.D.N.Y., No. 17-cv-09127, complaint filed 11/21/17).
The suit ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.